Research from the STEP trials (semaglutide) and SURMOUNT-4 (tirzepatide) shows that without ongoing pharmacotherapy or substantial behavioral interventions, significant weight regain occurs within the first year after stopping treatment
The Elephant in the Room: It's Still About Cost By far the most significant factor in a patient's decision
For example, following the induction of intestinal ischemia in humans, a rapid increase in GLP-1 secretion was observed, suggesting a link between endogenous LPS translocation and GLP-1 activation under conditions of barrier dysfunction ( Enterobacteriaceae and a concurrent decrease in acetic acid-producing bacteria, such as Bifidobacteria
2 Connect with a provider After evaluating your consultation, a provider licensed in your state will prescribe a weight management treatment plan (if clinically appropriate)
Boosting GLP-1 through a supplement doesnt really mean a whole lot, because the half-life is so shortbut even if it is elevated, we dont really know if its going to cause any of those beneficial effects, such as weight loss, Bloomer said
Understand that averages mask individual variation
